Legal lower age limitations (country specific)

Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE

Other indication for VKA than PE/DVT

More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW)heparin or initiation of VKA treatment prior to randomization

Participation in another pharmacotherapeutic study within the prior 30 days

Creatinine clearance \<10 mL/min, severe hepatic disease, or bacterial endocarditis

Life expectancy \<3 months

Active bleeding or high risk for bleeding

Uncontrolled hypertension: systolic blood pressure \>180 mm Hg or diastolic blood pressure \>110 mm Hg

Pregnancy or childbearing potential without proper contraceptive measures or women who are breastfeeding

Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin, enoxaparin, or tinzaparin

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism